Companies / Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

Nasdaq: TENXCIK 34956CHAPEL HILL, NC

Financials · FY2025

Revenue$0
Net income$-52.60M
Total debt—
Cash$118.00M
Diluted EPS$-1.34
Shares outstanding37.4M

Ownership

37.4M shares outstanding · as of Jul 28, 2026
0.03%Insiders
Ownership
Insiders0.03%10,000
Institutions36.21%13,552,485
Public float63.76%23,861,432

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 9

View all →
Insider% of sharesShares
Staab Thomas R IIChief Financial Officer
0.03%10,000
Almenoff June SherieDirector
——
Christopher Thomas GiordanoCEOCEO · Director
——
Davidson Michael H.Director
——
Doogan DeclanDirector
——
Hunter RobynDirector
——
McGauley ThomasInterim CFO
——
Proehl Gerald TDirector
——
Rich StuartChief Medical Officer · Director
——

Institutional holders 55

View all →
HolderValue% of shares
Janus Henderson Group PLC$29.07M4.85%
BlackRock, Inc.$25.14M4.62%
Perceptive Advisors LLC$23.15M3.87%
Ikarian Capital, LLC$11.80M2.59%
Adage Capital Partners Gp, L.L.C.$8.64M1.44%
Millennium Management LLC$8.54M1.43%
State Street Corporation$7.43M1.36%
Morgan Stanley$7.27M1.59%
TD Asset Management Inc$6.38M1.07%
Marshall Wace, LLP$5.64M0.94%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
May 11, 2026Staab Thomas R II
Executive
GrantCommon Stock$0+10K
10,000
0.03% of shares
low
May 11, 2026Staab Thomas R II
Executive
GrantStock Option (right to buy)—+450K
450,000
1.20% of shares
low
Jan 9, 2026Christopher Thomas Giordano
CEO
GrantStock Option (right to buy)—+450K
450,000
1.20% of shares
low
Jan 9, 2026Rich Stuart
Executive
GrantStock Option (right to buy)—+250K
250,000
0.67% of shares
low
Jan 9, 2026Hunter Robyn
Director
GrantStock Option (right to buy)—+30K
30,000
0.08% of shares
low
Jan 9, 2026Doogan Declan
Director
GrantStock Option (right to buy)—+30K
30,000
0.08% of shares
low
Jan 9, 2026Davidson Michael H.
Director
GrantStock Option (right to buy)—+30K
30,000
0.08% of shares
low
Jan 30, 2026McGauley Thomas
Executive
ExerciseStock Option (right to buy)—+50K
50,000
0.13% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Perceptive Advisors LLCPassive13G/A———
RTW Investments, LPPassive13G/A———
Point72 Asset Management, L.P.Passive13G/A———
Venrock Healthcare Capital Partners III, L.P.Passive13G/A———
Logos Global Management LPPassive13G———
Lind Global Fund II LPPassive13G/A———
Dellora Investments Master Fund LPPassive13G/A———
Biotechnology Value Fund L PPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
TENX——88032L605—